San Diego’s MappBio recently received a $14.8 million contract to advance a treatment for Sudan virus.
The money — from a division of the U.S. Department of Health and Human Services — is to move Mapp’s MBP134 through a phase 1 clinical trial. Under the contract Mapp is eligible for an additional $32 million, dependent on hitting milestones.
The goal is to be prepared for future outbreaks of Sudan virus, part of the same family of viruses as Ebola virus. Like Ebola, Sudan virus is known for severe fever and high mortality.
MappBio obtained an exclusive license to develop and commercialize the antibodies that make up MBP134.
The treatment was born of a private-public partnership between MappBio, the company Adimab, Albert Einstein College of Medicine, National Institute of Allergy and Infectious Diseases and other organizations.